CRSP vs NTLA
CRSP and NTLA side by side — valuation & fundamentals (public data).
Key statistics
| Metric | CRSPCRISPR THERAPEUTICS AG | NTLAINTELLIA THERAPEUTICS, INC. |
|---|---|---|
| Market cap | $5.17B | $1.67B |
| P/S | 1473.8x | 24.7x |
| Revenue growth (YoY) | -90.6% | 16.9% |
| Earnings growth (YoY) | -58.8% | 20.5% |
| EBIT margin | -18933.6% | -651.7% |
| ROE | -33.3% | -56.7% |
| ROIC | -32.6% | — |
| 1y total return | -4.4% | +4.2% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: CRSP vs NTLA
| 지표 | CRSP | NTLA |
|---|---|---|
| 최종 가치 | $38.0K | $9.5K |
| 총수익률 | +279.8% | -5.3% |
| CAGR | +14.6% | -0.6% |
| 변동성 | 64.1% | 78.7% |
| 샤프 | 0.47 | 0.34 |
| 소르티노 | 0.73 | 0.50 |
| 최대 낙폭 | -85.1% | -96.5% |
공통 거래일 2463일 기준, 2016-10-19 → 2026-08-07 · 무위험수익률 3.87% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)